<DOC>
	<DOCNO>NCT01155531</DOCNO>
	<brief_summary>The hypothesis study 150 mg sertraline 3 mg telenzepine safe , tolerable , effect suppress appetite , take combination daily mouth healthy , overweight , adult men woman . In study , 12 people assign one 4 group : A , B , C , D , receive 0 , 50 , 100 , 150 mg sertraline per day . People Groups B , C , D receive initial dose 50 mg sertraline . People Groups C D receive additional 50 mg sertraline per week . Up 10 people group able tolerate sertraline dose least 5 day begin take 50 mg sertraline plus dos telenzepine increase 1 mg 2 mg 3 mg 7-day period ( receive combination ) . On day begin take combination drug , appetite evaluate ( visual scale 0 100 ) 3 meal . The appetite person , assess visual scale , evaluate last day period ( Day 7 ) 3 meal combination treatment , stay research unit . The amount food eat determine . Based safety tolerability assessment individual , previous group receive low dos combination drug , decision make whether increase dose drug . Since appetite person evaluate last day period ( Day 7 ) 3 meal combination treatment , people study stay research unit approximately 2½ day , start Day 6 previous treatment , appetite evaluation make Day 7 fix meal even Day 6 . These people continue stay research unit begin telenzepine dose increase , 24 hour safety observation may make immediately increase . After final dos telenzepine receive , people Groups C D continue receive sertraline 50 mg per day additional 7 day study physician decides sertraline discontinue . People return study unit final visit , 2 week receive last sertraline dose .</brief_summary>
	<brief_title>Safety &amp; Tolerability Combination Antidepressant Peptic Ulcer Drug Overweight Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Pirenzepine</mesh_term>
	<mesh_term>Telenzepine</mesh_term>
	<criteria>In good health base medical history , physical examination , ECG , routine laboratory test , BMI &gt; /= 30 kg/m2 &lt; /=30 40 kg/m^2 . Males female agree use described birth control method . Nonsmoker . Willing able confined clinical research facility . Willing able comply protocol able communicate investigator . Able comprehend willing provide write informed consent . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , neurologic , allergic disease ( include drug allergy ; patient untreated , asymptomatic , seasonal allergy may enrol ) , surgical condition , cancer condition might opinion investigator impair ability subject complete study significantly interfere absorption , distribution , metabolism , excretion study drug . Evidence history clinically significant psychiatric disease include major depression , mania , hypomania , history suicide attempt suicidal ideation . Subjects Beck Depression InventoryII ( BDIII ) score &gt; 13 screening exclude . Clinically relevant abnormal finding screen examination ( include laboratory test ECG ) . Screening ECG demonstrate least one following : heart rate &gt; 100 bpm , QRS &gt; 120 msec , QTc &gt; 450 msec , PR &gt; 220 msec rhythm sinus rhythm , sinus bradycardia , sinus arrhythmia . Change weight &gt; 5 kilogram within 3 month screen . History alcohol consumption exceed 14 drinks/week ( 1 drink equal 5 ounce wine , 12 ounce beer , 1.5 ounce hard liquor ) within 6 month study entry . Sitting systolic blood pressure ≤90 millimeter mercury ( mmHg ) ≥140 mmHg , diastolic blood pressure &lt; /= 50 mmHg &gt; /= 90 mmHg judge clinically significant investigator . Positive result drug screen , hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) , human immunodeficiency ( HIV ) test . Use prescription nonprescription drug , vitamin , dietary supplement within 14 day prior first dose study medication . Subjects oral contraceptive subject use acetaminophen dos &lt; 2 grams/day eligible study entry . Any exception must felt impact integrity data must jointly agree upon investigator medical monitor . Treatment investigational drug , use know CYP450 enzyme inducing/inhibiting agent ( e.g. , barbiturate , phenothiazine , cimetidine , St. John 's Wort ) herbal supplement within 30 day prior first dose study medication . Treatment psychotropic medication within 90 day screen . History drug abuse dependence within 180 day screen . Febrile illness within 5 day prior first dose study medication . Inadequate venous access . Known allergy sertraline telenzepine . History active eating disorder anorexia nervosa , bulimia binge eat disorder . Elevated ALT ( &gt; 2X ULN ) total bilirubin ( &gt; 1.6 mg/dL ) Have diabetes mellitus ( fast plasma glucose &gt; 126 mg/dL ) Have weight loss medication past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Sertraline</keyword>
	<keyword>Telenzepine</keyword>
	<keyword>Decrease appetite</keyword>
	<keyword>Reduce appetite</keyword>
	<keyword>Lose weight</keyword>
</DOC>